Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199)

Duvelisib, an oral dual inhibitor of PI3K-δ and PI3K-γ, is in phase III trials for the treatment of chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin’s lymphoma (iNHL). In CLL, duvelisib monotherapy is associated with high iwCLL and nodal response rates, but complete remissions are rare. T...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leukemia
Main Authors: Patel, Viralkumar M., Balakrishnan, Kumudha, Douglas, Mark, Tibbitts, Thomas, Xu, Ethan Y., Kutok, Jeffery L., Ayers, Mary, Sarkar, Aloke, Guerrieri, Renato, Wierda, William G., O’Brien, Susan, Jain, Nitin, Stern, Howard M., Gandhi, Varsha
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5540815/
https://ncbi.nlm.nih.gov/pubmed/28017967
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2016.382
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados